Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis, CiRA Partner on Induced Pluripotent Stem Cell Technology Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French genome engineering firm Cellectis and the Center for iPS Cells Research and Application of Kyoto University today announced a collaboration to combine their technologies to develop induced pluripotent stem cells, or iPS, as cellular tools.

iPS cells are adult cells that have been reprogrammed to behave like embryonic stem cells and theoretically can differentiate into other cell types. However, the ethical controversies that have surrounded the use of embryonic stem cells are not associated with iPS, the two firms said in a statement.

The collaboration will combine Cellectis' genome engineering technology with CiRA's iPS technology "to rationally engineer the genome of these cells in order to provide better control over their behavior," they said in a joint statement.

Terms of the deal were not disclosed.

David Sourdive, executive vice president of corporate development for Paris-based Cellectis, added that the collaboration supports an approach developed by his firm with Ectycell, a subsidiary dedicated to the industrial use of iPS cells.

"Together, we believe we can maximize the natural synergy between these two complementary approaches to cell engineering to develop technology that could have a major impact in the stem cell field," he said.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.